Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
December 07 2021 - 6:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2021
Commission File Number: 001-32371
SINOVAC
BIOTECH LTD.
No. 39 Shangdi Xi Rd, Haidian District
Beijing 10085, People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Form 20-F x
Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
SINOVAC BIOTECH LTD.
|
|
|
|
|
By:
|
/s/ Nan Wang
|
|
Name:
|
Nan Wang
|
|
Title:
|
Chief Financial Officer
|
Date: December 7, 2021
Exhibit Index
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Sep 2023 to Sep 2024